Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Bumpy Q4 Could Double As Inflection Point
Tweet
Share
E-mailGet Alerts HITK Hot Sheet
Price: $43.49 --0%
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK) price target of $45.00.
Analyst, Randall Stanicky, said, "We are lowering fiscal Q4E EPS from $0.81 to $0.73 on a combination of lower cough and cold contribution and higher near-term SG&A spending. We see further headwinds for fiscal Q4 (week of July 9) largely due to a uniquely weak and well advertised cough and cold season. That said, the stock has pulled back - 25% YTD, and we see several drivers that can make the stock work in H2/2012 and beyond for those who can look past the quarter. We see the upcoming fiscal Q4 as an inflection with limited downside from here and make no change to our price target."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.15 yesterday.
Analyst, Randall Stanicky, said, "We are lowering fiscal Q4E EPS from $0.81 to $0.73 on a combination of lower cough and cold contribution and higher near-term SG&A spending. We see further headwinds for fiscal Q4 (week of July 9) largely due to a uniquely weak and well advertised cough and cold season. That said, the stock has pulled back - 25% YTD, and we see several drivers that can make the stock work in H2/2012 and beyond for those who can look past the quarter. We see the upcoming fiscal Q4 as an inflection with limited downside from here and make no change to our price target."
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Shares of Hi Tech Pharmacal closed at $29.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
- Goldman Sachs Downgrades Zhejiang Huayou Cobalt Co Ltd. (603799:CH) to Sell
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
